Impact of early benefit assessment on patients with epilepsy in Germany : Current healthcare provision and therapeutic needs.

[Impact of early benefit assessment on patients with epilepsy in Germany : Current healthcare provision and therapeutic needs]. Nervenarzt. 2016 Feb 29; Authors: Strzelczyk A, Hamer HM Abstract Epilepsy is one of the most common chronic neurological diseases and represents a significant burden for patients, their families and society. In more than 75 % of patients anticonvulsant therapy consists of valproate, carbamazepine, lamotrigine or levetiracetam. There is a need for polytherapy in drug-refractory patients and they suffer from negative effects on quality of life and employment that is associated with high indirect costs. To allow a comprehensive treatment in this patient group, access to new anticonvulsants with novel modes of action is needed; however, all applications for new antiepileptic drugs failed to prove added benefits during the Pharmaceutical Market Restructuring Act (AMNOG) in Germany. One of the main reasons is the mandatory definition of a standard comparative therapy. It remains unclear whether there will be studies in the future which will fulfill the requirements of the current version of AMNOG. Observational studies after approval and marketing of new antiepileptic drugs could be better alternatives to prove added benefits for individual patients in the current German healthcare system. PMID: 26927680 [PubMed - as supplied by publisher]
Source: Der Nervenarzt - Category: Neurology Authors: Tags: Nervenarzt Source Type: research

Related Links:

ConclusionsThe majority of patients received new AEDs. The combination of classic and new AEDs was more frequently prescribed to patients with refractory epilepsy or with associated comorbidities.ResumenObjetivoCuantificar el tipo de fármacos antiepilépticos (FAEs), empleados en epilepsia, en consultas de neurología.Material y métodoEstudio descriptivo observacional sobre una muestra de 559 pacientes mayores de 14 años con epilepsia y en tratamiento farmacológico, recogidos en consultas ambulatorias por 47 neurólogos en España en mayo del año 2016.Para las clas...
Source: Neurologia - Category: Neurology Source Type: research
Publication date: Available online 10 November 2019Source: The Veterinary JournalAuthor(s): M. Portero, E. Martínez de Merlo, C. Pérez, M. Benito, M.A. Daza, C. FragioAbstractMeningoencephalitis of unknown origin (MUO) is a common inflammatory disease of the central nervous system. Several studies investigated finding prognostic factors, but results are contradictory. The aim of this study was to determine the concentrations of blood lactate (Blood-L) and cerebrospinal fluid lactate (CSF-L) in dogs with MUO for prognostic purposes. A total of 45 dogs with MUO (MUO group) and 11 with idiopathic epilepsy (IE gr...
Source: The Veterinary Journal - Category: Veterinary Research Source Type: research
ConclusionPCDH19 mutation can be inherited or de novo. The clinical spectrum ofPCDH19 mutation includesPCDH19 Girls Clustering Epilepsy with or without mental retardation, psychosis, and asymptomatic male. The onset age ofPCDH19 Girls Clustering Epilepsy can range from infancy to adulthood. Sisters in the same family may be sensitive to the same antiepileptic drugs. And our report expands the mutation spectrum ofPCDH19 Girls Clustering Epilepsy.
Source: Brain and Behavior - Category: Neurology Authors: Tags: ORIGINAL RESEARCH Source Type: research
Epileptic activity without visible convulsions is common in Alzheimer's disease (AD) and may contribute adversely to the disease progress and symptoms. Transgenic mice with amyloid plaque pathology also display epileptic seizures, but those are too infrequent to assess the effect of anti-epileptic treatments. Besides spontaneous seizures, these mice also display frequent epileptic spiking in epidural EEG recordings, and these have provided a means to test potential drug treatment to AD-related epilepsy. However, the origin of EEG spikes in transgenic AD model mice has remained elusive, which makes it difficult to relate el...
Source: Frontiers in Neurology - Category: Neurology Source Type: research
ConclusionsWe suggest thatde novo AS may be a well-defined age-related and self-limited epilepsy syndrome, with a good prognosis and excellent response to therapy, but it comes with a high risk of relapsing if not adequately treated with antiepileptic drugs.
Source: Seizure - Category: Neurology Source Type: research
Source: BMJ News - Category: General Medicine Source Type: research
The change comes after two highly publicized cases in which young epileptic patients depended on the treatments.
Source: NYT Health - Category: Consumer Health News Authors: Tags: Cannabis Foods and Products Epilepsy Medical Marijuana Multiple Sclerosis Drugs (Pharmaceuticals) Chemotherapy England Wales Source Type: news
Children with two rare life-threatening forms of epilepsy will now have access to the drug Epidyolex, which helps to reduce seizures. Patients with MS will be offered a cannabis-based spray.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
Politicians running scared of big pharma and the taboo around cannabis are blocking access to these vital drugsThat the government will allow a few serious epilepsy and multiple sclerosis sufferers to getcannabidiol medicine to relieve their symptoms is good news. That is all that can be said. Once more a decision emerges from the caverns of Britain ’s NHS that reveals the evils of a politicised, centralised, deadened health service.Related:Legalisation of cannabis in the UK would help protect its users from harm | James NichollsContinue reading...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: Cannabis Drugs Society NHS Health Epilepsy UK news Science Pharmaceuticals industry Business David Nutt Source Type: news
(University of Wisconsin-Madison) By electrically stimulating nerves, neuromodulation therapies can reduce epileptic seizures, soothe chronic pain, and treat depression and a host of other health conditions without the use of conventional drugs like opioids. Now, University of Wisconsin-Madison biomedical engineers and their collaborators have made a significant advance that could dramatically reduce the cost of neuromodulation therapy, increase its reliability and make it much less invasive.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
More News: Carbamazepine | Employment | Epilepsy | Lamictal | Marketing | Neurology | Study